Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors
- 15 January 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (2) , 223-231
- https://doi.org/10.1200/jco.2003.12.120
Abstract
Purpose: Endostatin is the first endogenous angiogenesis inhibitor to enter clinical trials. Laboratory investigations with endostatin have indicated broad antitumor activity coupled with remarkabl...Keywords
This publication has 43 references indexed in Scilit:
- The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healingThe FASEB Journal, 2000
- Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosisArthritis & Rheumatism, 2000
- Endostatin Inhibits Microvessel Formation in the ex Vivo Rat Aortic Ring Angiogenesis AssayBiochemical and Biophysical Research Communications, 2000
- Collagen XVIII/Endostatin Structure and Functional Role in Angiogenesis.Cell Structure and Function, 2000
- Inhibitory Effect of Full-Length Human Endostatin on in Vitro AngiogenesisBiochemical and Biophysical Research Communications, 1999
- Endostatin Binds to Blood Vessels in Situ. Independent of Heparan Sulfate and Does Not Compete for Fibroblast Growth Factor-2 BindingThe American Journal of Pathology, 1999
- Serum Concentrations of Endostatin in Patients with Vulvar CancerGynecologic Oncology, 1999
- Cloning, Expression, andin VitroActivity of Human EndostatinBiochemical and Biophysical Research Communications, 1999
- Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic ActivityBiochemical and Biophysical Research Communications, 1998
- New perspectives in clinical oncology from angiogenesis researchEuropean Journal Of Cancer, 1996